Back to top
more

SARTORIUS (SARTF)

(Delayed Data from OTC)

$252.54 USD

252.54
3

+4.54 (1.83%)

Updated May 3, 2024 02:39 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Omnicell (OMCL) Hits 52-Week High, Can the Run Continue?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 Reasons Why SARTORIUS AG (SARTF) Is a Great Growth Stock

SARTORIUS AG (SARTF) possesses solid growth attributes, which could help it handily outperform the market.

Earnings Estimates Rising for SARTORIUS AG (SARTF): Will It Gain?

SARTORIUS AG (SARTF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

What Makes SARTORIUS AG (SARTF) a New Buy Stock

SARTORIUS AG (SARTF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SARTORIUS AG (SARTF) Beats Q2 Earnings and Revenue Estimates

SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 10.45% and 5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS AG (SARTF) to Report Q2 Results: Wall Street Expects Earnings Growth

SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

Urmimala Biswas headshot

5 MedTech Stocks to Gain in 2021 as Base Business Recovers

These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SARTORIUS AG (SARTF) Tops Q1 Earnings and Revenue Estimates

SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 10.84% and 6.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS AG (SARTF) Earnings Expected to Grow: Should You Buy?

SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has SARTORIUS (SARTF) Outpaced Other Medical Stocks This Year?

Is (SARTF) Outperforming Other Medical Stocks This Year?

SARTORIUS AG (SARTF) Misses Q3 Earnings Estimates

SARTORIUS AG (SARTF) delivered earnings and revenue surprises of -7.78% and 4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?

HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SARTORIUS AG (SARTF) Tops Q2 Earnings and Revenue Estimates

SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 8.75% and 6.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS AG (SARTF) to Report Q2 Results: Wall Street Expects Earnings Growth

SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SARTORIUS AG (SARTF) Surpasses Q1 Earnings and Revenue Estimates

SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 24.62% and 12.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for April 18th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

SARTORIUS AG (SARTF) to Report Q1 Results: What to Know Ahead of the Release

SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medical Product's Q4 Earnings on Feb 24: VWR, SARTF, HMSY

Let's take a look at the major Medical Product stocks slated to release their fourth-quarter 2016 numbers on Feb 24.